Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ekso Bionics Holdings (EKSO) Gains from Investment Securities (2016 - 2025)

Ekso Bionics Holdings (EKSO) has disclosed Gains from Investment Securities for 5 consecutive years, with $92000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Gains from Investment Securities changed N/A to $92000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $92000.0, a N/A change, with the full-year FY2021 number at -$134000.0, down 139.29% from a year prior.
  • Gains from Investment Securities was $92000.0 for Q3 2025 at Ekso Bionics Holdings, up from $11000.0 in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $254000.0 in Q3 2023 to a low of -$131000.0 in Q4 2021.
  • A 3-year average of $56500.0 and a median of $51500.0 in 2025 define the central range for Gains from Investment Securities.
  • Biggest YoY gain for Gains from Investment Securities was 13000.0% in 2021; the steepest drop was 13000.0% in 2021.
  • Ekso Bionics Holdings' Gains from Investment Securities stood at -$131000.0 in 2021, then surged by 293.89% to $254000.0 in 2023, then crashed by 63.78% to $92000.0 in 2025.
  • Per Business Quant, the three most recent readings for EKSO's Gains from Investment Securities are $92000.0 (Q3 2025), $11000.0 (Q2 2025), and $254000.0 (Q3 2023).